Why the study?
Clinical use of the antineoplastic agent doxorubicin is limited by cardiotoxicity, prompting investigation into whether olmesartan, l-carnitine, or their combination provides cardioprotection.
Do olmesartan and l-carnitine protect against doxorubicin-induced cardiotoxicity in a rat model?
Population
Male albino rats randomly divided into seven groups of n = 8
Comparison
Olmesartan, l-carnitine, and their combination vs DOX, normal control, and single-agent controls
Design
Randomized animal study
Follow-up
2 weeks
Authors
Loading...
Should not yet change practice; leaves open human confirmation of this combination against doxorubicin cardiotoxicity.
Do olmesartan and l-carnitine protect against doxorubicin-induced cardiotoxicity in a rat model?
Olmesartan and l-carnitine demonstrate protective effects against doxorubicin-induced cardiotoxicity in a rat model through antioxidant, anti-inflammatory, and antiapoptotic mechanisms.
Aziz et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: